Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous neridronic acid versus placebo for complex regional pain syndrome
2017-004244-37Phase 3Completed
- Sponsor
- Grünenthal GmbH
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of neridronic acid in complex regional pain syndrome (CRPS) and Complex Regional Pain Syndrome Type 1 (CRPS-1) (2 arms), sponsored by Grünenthal GmbH. Primary endpoint: Change from baseline to Week 12 in average pain intensity score. Started May 2018; status: completed.
02
Drugs
neridronic acid
03
Conditions
complex regional pain syndrome (CRPS)Complex Regional Pain Syndrome Type 1 (CRPS-1)
Beyond the preview
Go deeper on 2017-004244-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004244-37.